Pulse Biosciences (PLSE) FCF Margin (2021 - 2025)
Pulse Biosciences' (PLSE) quarterly FCF Margin came in at 15377.91% in Q3 2025, down 211.25% quarter-over-quarter from 4940.75% in Q2 2022.
Pulse Biosciences (PLSE) FCF Margin (2021 - 2025) Analysis & Trends
Pulse Biosciences' FCF Margin history runs 3 years deep, the most recent figure standing at 15377.91% for Q3 2025.
- On a quarterly basis, FCF Margin changed N/A year-over-year to 15377.91% in Q3 2025; TTM through Sep 2025 was 56688.37%, a N/A change from a year earlier, with the FY2022 full-year figure at 6773.43%, down 290743.0% from the prior year.
- FCF Margin retreated to 15377.91% in Q3 2025 per PLSE's latest filing, from 4940.75% in the prior quarter.
- Across five years, FCF Margin topped out at 1503.39% in Q4 2021 and bottomed at 15377.91% in Q3 2025.
- The 3-year median for FCF Margin is 3518.24% (2022), against an average of 5538.69%.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 20.74% |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 37.88% |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | 11.58% |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 4.30% |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 36.36% |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 9.26% |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | 8.91% |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | -13.60% |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 11.56% |
| 10 | Pulse Biosciences | 2.09 Bn | 2.01 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -15,377.91% |
| Jun 30, 2022 | -4,940.75% |
| Mar 31, 2022 | -3,518.24% |
| Dec 31, 2021 | -1,503.39% |
| Sep 30, 2021 | -2,353.14% |